Home
Conditions
Neoplasms by Histologic Type

Clinical trial condition

Neoplasms by Histologic Type

Explore clinical trials studying Neoplasms by Histologic Type. Study availability and eligibility vary by location and protocol.

27 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Neoplasms by Histologic Type trial results

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282

Conditions: Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +19 more
Locations: Hospital Clínico Universitario de Santiago Santiago de Compostela, A Coruña, Spain

Hospital Universitario Virgen de las Nieves Granada, Andalusia, Spain

Hospital Unviersitari Son Espases Palma de Mallorca, Balearic Islands, Spain

Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain

View all 20 locations

View Trial Details

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

NCT05252078

Conditions: Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
Locations: Jiangxi Cancer Hospital Nanchang, Jiangxi, China

View Trial Details

Not yet recruiting

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541

Conditions: Adenocarcinoma, Carcinoma, Genital Diseases, +12 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT05797246

Conditions: Communicable Diseases, DNA Virus Infections, Disease Attributes, +18 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451

Conditions: Antineoplastic Agents, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, +15 more
Locations: University of Chicago Medical Center Chicago, Illinois, United States

UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States

View Trial Details

Active, not recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

NCT02690545

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

View Trial Details

Active, not recruiting

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +7 more
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

Wake Forest University Winston-Salem, North Carolina, United States

View Trial Details

Active, not recruiting

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

NCT04124198

Conditions: Carcinoma, Carcinoma, Squamous Cell, Communicable Diseases, +29 more
Locations: Aarhus University Hospital Aarhus, Denmark

Copenhagen University Hospital Rigshospitalet Copenhagen, Denmark

Odense University Hospital Odense, Denmark

View Trial Details

Active, not recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

NCT04807166

Conditions: Adnexal Diseases, Angiogenesis, Anlotinib, +22 more
Locations: Huai'an First People's Hospital Huai'an, China

Nanjing Drum Tower Hospital Nanjing, China

Zhongda Hospital Southeast University Nanjing, China

The First Affiliated Hospital of Soochow University Suzhou, China

View Trial Details

Completed

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

NCT02158858

Conditions: Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Disease, +23 more
Locations: Mayo Clinic Arizona Phoenix, Arizona, United States

UCLA Medical Center Los Angeles, California, United States

Mayo Clinic Jacksonville Jacksonville, Florida, United States

Northwestern University - Lurie Comprehensive Cancer Center Chicago, Illinois, United States

View all 48 locations

View Trial Details

Neoplasms by Histologic Type

Neoplasms by Histologic Type trial results

Related conditions